TRDA — Entrada Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1689375 ·
Last close
$6.79
Market Cap
$263.59M
52W High
$16.45
52W Low
$5.63
ADV30
429,023
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 875,000 | — | -42,303,000 | -39,717,000 | 335,518,000 | 76,444,000 | 64,664,000 |
| Dec 2025 | 1,299,000 | — | -42,208,000 | -39,164,000 | 377,378,000 | 90,394,000 | 71,245,000 |
| Sep 2025 | 1,614,000 | — | -47,051,000 | -44,134,000 | 412,898,000 | 93,286,000 | 72,182,000 |
| Jun 2025 | 1,950,000 | — | -46,849,000 | -43,103,000 | 448,783,000 | 72,482,000 | 69,278,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-128,512,000
Investing CF
$116,808,000
Financing CF
$887,000
CapEx
$-2,693,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.46
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-273,094,000
Inventory
—
Receivables
$1,177,000
ST Investments
$205,304,000
EBIT TTM
$-157,898,000
Pretax Income TTM
$-142,826,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,738,000
EBITDA
$-172,556,000
Free Cash Flow
$-75,381,376
Enterprise Value
$39,558,792
Total Cash
$254,859,008
Total Debt
$49,750,000
Shares Out
38,820,616
Trailing EPS
$-4.00
Book Value
$7.52
ROE
-48.3%
ROA
-26.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 25,421,000 | -157,898,000 | -143,750,000 | 377,378,000 | 71,245,000 | — | -128,512,000 |
| Dec 2024 | 210,782,000 | 47,011,000 | 65,626,000 | 526,321,000 | 97,643,000 | — | -41,557,000 |
| Dec 2023 | 129,013,000 | -3,162,000 | -6,685,000 | 469,192,000 | 226,832,000 | — | 139,803,000 |
| Dec 2022 | 0 | -97,248,000 | -94,616,000 | 252,056,000 | 39,502,000 | — | -93,786,000 |
TTM Snapshot
Revenues TTM
$63,305,000
NetIncome TTM
$-18,138,000
OpCashFlow TTM
$0
Assets (Latest)
$526,321,000
Forward EPS
$-3.26
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $6.79 · call volume: 3 · put volume: 16
Expected Move to 2026-09-18:
±$2.34
(34.46%) —
implied range
$4.45 –
$9.13
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $262.93M | $0.16 | — |
| FHTX | Foghorn Therapeutics Inc. | $265.97M | $4.53 | — |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $261.05M | $1.94 | — |
| ELDN | Eledon Pharmaceuticals, Inc. | $260.89M | $3.38 | — |
| SLGL | Sol-Gel Technologies Ltd. | $266.92M | $82.25 | — |
News headlines (Yahoo Finance, 1h cache)
Wave Life Sciences (WVE) Reports Q2 Loss, Misses Revenue Estimates
2026-07-30 13:35 · Yahoo
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
2026-06-02 11:00 · Yahoo
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 20:30 · Yahoo
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
2026-05-09 06:07 · Yahoo
Entrada’s stock drops as DMD drug’s efficacy falls short
2026-05-08 10:39 · Yahoo
Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?
2026-05-07 20:04 · Yahoo
Sector Update: Health Care Stocks Softer Late Afternoon
2026-05-07 19:44 · Yahoo
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 12:50 · Yahoo
Entrada shares dive as Duchenne results disappoint
2026-05-07 11:14 · Yahoo
Entrada Therapeutics Reports First Quarter 2026 Financial Results
2026-05-07 11:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.